SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2003
ORPHAN MEDICAL, INC.
--------------------
(Exact name of registrant as specified in its charter)
Delaware 0-24760 41-1784594
-------- ------- ----------
(State or other jurisdiction (Commission file number) (I.R.S. employer
of incorporation) identification number)
Suite 250,
13911 Ridgedale Drive,
Minnetonka, MN 55305 (952) 513-6900
---------------------- ----- --------------
(Address of principal executive (zip code) (Registrant's telephone number,
offices) including area code)
Not Applicable
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events.
The Company completed the sale of Sucraid on May 5, 2003. The Company received
$1.5 million of proceeds from the transaction. This transaction was discussed in
the Company's press release dated April 30, 2003. The press release is attached
as Exhibit 99.1 to this Form 8-K.
Item 7. Financial Statements and Exhibits
Exhibit 99.1 - Press release dated April 30, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 7, 2003 ORPHAN MEDICAL, INC.
/s/ Timothy G. McGrath
----------------------------------
Timothy G. McGrath
Chief Financial Officer
(duly authorized officer and
principal financial officer)
EXHIBIT INDEX
Exhibit
Number Description
99.1 Press release dated April 30, 2003.